查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1775570

医疗保健契约製造(CMO) 市场：2025-2030 年预测

Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

医疗保健契约製造(CMO) 市场预计将从 2025 年的 2,006.27 亿美元成长到 2030 年的 2,901.76 亿美元，复合年增长率为 7.66%。

与其他产业一样，医疗保健产业也在药品和医疗设备的生产中利用外包流程。契约製造是将药品和医疗设备的生产外包给专门从事此项业务的外包公司的做法。随着患者数量的增加，医院面临维持充足设施的压力，这些设施需要在基础设施、人力、医疗照护、设备等方面满足预期。与製药和医疗设备製造商一样，医疗保健产业也在寻求将部分流程外包，以便专注于核心竞争力，同时最大限度地降低营运成本。

医疗保健契约製造（CMO）市场趋势：

医疗契约製造市场的经验和专业知识正在推动需求。此外，医疗保健提供者可以避免不必要的资本支出，从而避免管理资源紧张。寻求进入医疗保健市场的新参与企业可以透过外包药品和医疗设备的生产来生存，同时提供优质服务。成本因素是医疗合约製造市场蓬勃发展的主要原因。避免聘请专家并节省时间是该市场客户获得的额外好处。

医疗保健契约製造市场的成长动力：

  • 在预测期内，提高生产力并减少错误发生的可能性将有助于市场成长。

医疗保健行业的失误可能会对患者造成致命打击，并摧毁服务供应商辛苦赚来的收益。医疗保健CMO公司往往紧跟产业最新变化，并且能够为客户提供最佳解决方案。这推动了该行业公司的成长。药物研发成本高昂，这也是医疗保健CMO产业蓬勃发展的主要原因之一。

此外，政府施压要求在确保病患安全的同时保持竞争力和效率，这正在影响医疗保健产业的转型方向。专利到期也是企业转向医疗保健CMO的主要原因。规模经济使CMO公司能够最大限度地降低药品生产成本并维持利润，同时使医疗保健提供者能够保留增量收益。

医疗保健契约製造市场的地理展望：

  • 由于已开发国家对医疗保健 CMO 公司的高度依赖，预计亚太地区在预测期内将出现高成长。

为了满足日益增长的外科医疗设备和其他医疗辅助设备的需求，印度等国家正在将这些设备的製造外包，同时维持品质标准。美国等新兴国家正大力投资更新和升级其生产设施，以提高生产效率。由于拥有大量製药公司，美国占据了相当大的市场派饼。由于政府的大力支持和生物製药行业的蓬勃发展，欧洲地区也占据了相当大的市场份额。

医疗保健契约製造市场产品供应

  • Lonza cGMP 製造：三大洲的 cGMP 製造能力涵盖自体和同种异体细胞疗法以及基于病毒载体的基因疗法，使我们能够支持处于临床开发各个阶段的新型疗法的商业化。
  • AGC Biologics (AGC Inc) 配方开发：AGC Biologics 开发冷冻干燥、液体和药物产品配方，包括优化的冷冻干燥週期。我们运用实验设计 (DOE) 原则，进行广泛且快速的辅料筛检实验，以尽可能辨识出能够提高产品稳定性的辅料和条件。我们透过即时快速的稳定性测试，精心组合各种辅料和条件，以生产出理想的配方。我们生产的配方剂量浓度从微克到 175 mg/mL 以上。

医疗保健契约製造市场公司：

  • Pfizer Inc.
  • Lonza Group
  • AGC Biologics（AGC Inc）
  • Recipharm AB
  • Catalent, Inc.（Novo Holding A/S）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 医疗保健契约製造（CMO）市场（按服务）

  • 介绍
  • 製药CMO
    • 活性药物成分 (API) 製造
    • 最终剂量配方（FDF）製造
      • 注射剂型
      • 固态剂型
      • 半固态製剂
      • 液体製剂
    • 包裹
  • 医疗设备CMO
    • 设计外包
    • 设备製造
    • 最终组装

6. 医疗保健契约製造（CMO）市场（按产品类型）

  • 介绍
  • 已灭菌
  • 非无菌

7. 医疗保健契约製造（CMO）市场（按最终用户）

  • 介绍
  • 製药公司
  • 医疗设备公司
  • 其他的

8. 医疗保健契约製造（CMO）市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章：竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章：公司简介

  • Jubilant Pharma Limited
  • Pfizer Inc.
  • Lonza Group AG
  • AGC Biologics（AGC Inc）
  • Recipharm AB
  • Catelent Inc（Novo Holding A/S）
  • Aenova Group
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc
  • Fresenius Kabi AG

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610053

The Healthcare Contract Manufacturing Outsourcing (CMO) Market is expected to grow from US$200.627 billion in 2025 to US$290.176 billion in 2030, at a CAGR of 7.66%.

Like every other business, the Healthcare Sector also leverages the outsourcing process in the manufacture of drugs or medical devices. Contract manufacturing is a method for getting drugs and devices manufactured by an outsourcing firm specializing in that business. The increasing number of patients puts pressure on hospitals to maintain appropriate facilities to meet expectations in terms of infrastructure, workforce, medicine, and equipment. Outsourcing of some of the processes, like drug or medical device manufacturers, is being demanded by the healthcare sector to be able to focus on core competencies while minimizing the cost of operations.

Healthcare Contract Manufacturing Outsourcing (CMO) Market Trends:

Experience and expertise in the Healthcare outsourcing manufacturing market are driving the demand for such a market. On top of that, healthcare providers can avoid unnecessary capital investments, which might strain their resources. New players, willing to enter the healthcare market, can outsource the manufacture of drugs and devices to sustain their existence while providing quality services. The cost factor is the major reason for the booming Healthcare CMO market. Bypassing the process of hiring experts and saving time is an added advantage for the customers of this market.

Healthcare Contract Manufacturing Outsourcing Market Growth Drivers:

  • The increased productivity while reducing the probability of errors is contributing to the market growth in the forecast period.

Mistakes in the healthcare sector can be fatal for the patient and destroy the hard-earned earnings of the service provider. Healthcare CMO companies tend to remain up-to-date with the latest changes in the industry and can provide optimal solutions to their customers. This adds to the growth of the companies in this sector. Drug R&D is an expensive endeavor, which is one of the primary reasons why the Healthcare CMO Industry is thriving.

Besides, governmental pressure to remain competitive and efficient while ensuring the safety of patients is shaping the way the healthcare sector is transforming. Patent expiration is also a major reason why companies are resorting to a healthcare CMO. Due to economies of scale, CMO companies are able to minimize the cost of drug production and can maintain their profits while letting the healthcare service provider maintain their incremental profit.

Healthcare Contract Manufacturing Outsourcing Market Geographical Outlook:

  • The Asia Pacific region is expected to show higher growth prospects in the forecast period due to high dependence on healthcare CMO firms from developed countries.

To meet the rising demand for medical equipment for surgeries and other medical aids, countries, such as India, are outsourcing the manufacture of these devices while maintaining their quality standards. Developed countries, such as America, have significantly invested in updating and upgrading their facilities and enhancing production more efficiently. America shares a substantial portion of the pie of this market due to the presence of a large number of pharmaceutical companies. The European region also holds a major portion of the market due to high governmental support and the booming biopharmaceutical sector.

Healthcare Contract Manufacturing Outsourcing Market Product Offerings:

  • Lonza cGMP Manufacturing: Autologous and allogeneic cell treatments, as well as viral vector gene therapy, are all covered by cGMP manufacturing capabilities, which span three continents. It can aid in the commercialization of novel treatments at various phases of their clinical development. The NPI program uses experience and decades of expertise in building cGMP manufacturing standards, combining corporate and local quality standards, tailored for cell and gene therapies, to reduce the risk associated with clients' path to commercialization.
  • AGC Biologics (AGC Inc) formulation development: AGC Biologics creates formulations for lyophilized drug products, liquid drug substances, and drug products (together with optimized lyophilization cycles). Utilizing Design of Experiment (DOE) principles, they create extensive, quick excipient screening experiments to find excipients and circumstances that promote the greatest possible product stability. To produce an ideal formulation, they carefully examine various excipients and circumstances in combination using real-time and expedited stability studies. Formulations are created at dosage concentrations ranging from micrograms to >175 mg/mL.

Healthcare Contract Manufacturing Outsourcing Market Companies:

  • Pfizer Inc.
  • Lonza Group
  • AGC Biologics (AGC Inc)
  • Recipharm AB
  • Catalent, Inc. (Novo Holding A/S)

Healthcare Contract Manufacturing Outsourcing (CMO) Market Segmentation

By Service

  • Pharmaceutical CMO
  • Active Pharmaceutical Ingredients (API) Manufacturing
  • Final Dose Formulation (FDF) Mnuafacturing
  • Packaging
  • Medical Device (CMO)
  • Design Outsourcing
  • Device Manufacturing
  • Final Goods Assembly

By Product Type

  • Sterile
  • Non-Sterile

By End-User

  • Pharmaceutical Companies
  • Medical Device Companies
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indoensia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY SERVICE

  • 5.1. Introduction
  • 5.2. Pharmaceutiucal CMO
    • 5.2.1. Active Pharmaceutical Ingredients (API) Manufacturing
    • 5.2.2. Final Dose Formulation (FDF) Mnuafacturing
      • 5.2.2.1. Injectable Dose Formulation
      • 5.2.2.2. Solid Dose Formulation
      • 5.2.2.3. Semi-Solid Formulation
      • 5.2.2.4. Liquid Dose Formulation
    • 5.2.3. Packaging
  • 5.3. Medical Device CMO
    • 5.3.1. Design Outsourcing
    • 5.3.2. Device Manufacturing
    • 5.3.3. Final Good Assembly

6. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Sterilized
  • 6.3. Non-Sterilized

7. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharamceutcial Companies
  • 7.3. Medical Device Companies
  • 7.4. Others

8. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO)MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Jubilant Pharma Limited
  • 10.2. Pfizer Inc.
  • 10.3. Lonza Group AG
  • 10.4. AGC Biologics (AGC Inc)
  • 10.5. Recipharm AB
  • 10.6. Catelent Inc (Novo Holding A/S)
  • 10.7. Aenova Group
  • 10.8. Boehringer Ingelheim International GmbH
  • 10.9. AbbVie Inc
  • 10.10. Fresenius Kabi AG

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations